Does tirzepatide improve cardiovascular outcomes and quality of life in patients with heart failure with preserved ejection fraction and obesity?

In patients with heart failure with preserved ejection fraction and obesity, tirzepatide reduced the risk of cardiovascular death or worsening heart failure and improved health status compared with placebo.

Randomized trial · NEJM 2025

Reference: Packer M, Zile MR, Kramer CM. N Engl J Med. 2025; PMID: 39555826

Chapters

0:00 Intro

0:38 The trial

3:27 My take

4:02 Outro

Read the structured trial summary at hormoneinsight.com

This podcast is intended for healthcare professionals only. It is educational and is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.

AI narration disclosure: This episode uses AI-generated narration.

For healthcare professionals. Educational content only; not medical advice or a substitute for clinical judgement, individual assessment or current guidance.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en